Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Amadeus company Solexa agrees $600 million merger

Wednesday November 15th 2006 -- Amadeus portfolio company, Solexa Inc. (NASDAQ: SLXA) has entered into a definitive merger agreement with Illumina Inc. (NASDAQ: ILMN), whereby Illumina will acquire all Solexa shares in a stock-for-stock transaction. Solexa stockholders will receive, subject to certain 'collar' provisions, shares of Illumina common stock valued at $14 per Solexa share, representing a total equity consideration of approximately $600 million. Amadeus first backed Solexa in 2001 and, at the time of this agreement, was Solexa's largest single shareholder with some 12.5% holding.

Solexa, headquartered in Hayward, California with its R&D centre near Cambridge UK, has developed a proprietary, next generation genetic analysis system for use in whole genome sequencing, targeted resequencing, digital gene expression and microRNA analysis. Illumina develops and markets next-generation tools for the large-scale analysis of genetic variation and function, including a targeted set of offerings for organisations conducting larger-scale research in the areas of genotyping and gene expression profiling.

The merger creates the only company with genome-scale technology for genotyping, gene expression and sequencing.

Hermann Hauser, Director of Amadeus ad a member of the Board of Solexa, says: 'This deal is a great opportunity for Solexa and Illumina to build on world leadership in genetic analysis technology and shows, yet again, that we in Europe can develop world class technologies into world class businesses. Our congratulations are due to Solexa's founding scientists, Dr Shankar Balasubramanian and Dr David Klenerman, faculty members in the Chemical Laboratories at the University of Cambridge and the management team under the leadership of John West.'

For further information, please contact:
Hermann Hauser or Andrey Kessel, Amadeus Capital Partners, 01223 707000
Chantal Ligertwood, PR for Amadeus, 07976 229210

About Amadeus (
Amadeus is one of Europe's leading technology investors. Since its inception in 1997, the firm has backed nearly 60 companies covering computer hardware and software, mobile and fixed communications technologies and medical technologies. Investments include Cambridge Silicon Radio, producing single chip bluetooth radios for short range connections and floated on the London Stock Exchange in 2004, Optos, a manufacturer of laser retinal scanners which this year had a successful IPO on the London Stock Exchange, Cambridge Broadband, developing technologies for wireless broadband networks in countries with poor infrastructure and Valista, an electronic payments company.

Publisher Contact Information:

Amadeus Capital Partners Limited
+44 (0)7976 229210

Company profile of Amadeus Capital Partners Limited
Past press releases of Amadeus Capital Partners Limited.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Dec 21€50.0MKnowledge management
Dec 20€16.0MSemiconductors
Dec 17€18.0MOther Computers & Electronics
Dec 17€5.2MBiotechnology
Dec 17€17.0MBusiness applications
Dec 15€17.0ME-Commerce
Dec 4€3.3MNanotechnology

For information on Europe's most extensive database on technology funding click here!


Press Releases

Sep 30
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

About usContact usLegal Information
Copyright 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.